These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21252245

  • 1. Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.
    White HD, Ahmad AM, Durham BH, Joshi AA, Fraser WD, Vora JP.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):726-36. PubMed ID: 21252245
    [Abstract] [Full Text] [Related]

  • 2. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.
    Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R, Ibrahim H, Durham BH, Vora JP, Fraser WD.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2860-8. PubMed ID: 12788900
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients.
    White HD, Ahmad AM, Durham BH, Patwala A, Whittingham P, Fraser WD, Vora JP.
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3371-80. PubMed ID: 15741264
    [Abstract] [Full Text] [Related]

  • 4. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
    White HD, Ahmad AM, Syed AA, Clewes A, Peter R, Vora JP, Fraser WD.
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):516-26. PubMed ID: 15049968
    [Abstract] [Full Text] [Related]

  • 5. PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD.
    White HD, Ahmad AM, Durham BH, Peter R, Prabhakar VK, Corlett P, Vora JP, Fraser WD.
    J Bone Miner Res; 2007 Nov; 22(11):1798-807. PubMed ID: 17645402
    [Abstract] [Full Text] [Related]

  • 6. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP.
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [Abstract] [Full Text] [Related]

  • 7. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 9. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 10. Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency.
    Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH, Vora JP.
    Bone; 2003 Feb; 32(2):170-9. PubMed ID: 12633789
    [Abstract] [Full Text] [Related]

  • 11. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 12. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity.
    White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD, Vora JP.
    J Clin Endocrinol Metab; 2006 Mar; 91(3):913-9. PubMed ID: 16352693
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 14. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 15. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 16. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 17. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 19. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
    Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E.
    Transplantation; 2006 Mar 15; 81(5):686-91. PubMed ID: 16534469
    [Abstract] [Full Text] [Related]

  • 20. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 15; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.